CA-DIGITATE
27.10.2021 15:02:05 CEST | Business Wire | Press release
Digitate , a SaaS-based, leading provider of autonomous enterprise solutions, today announced its recognition as a market and category leader in AIOps by multiple leading analyst firms and industry reports. Digitate earned these merits as a result of its high customer ratings and wide breadth of solutions that span across IT and business operations, as well as assurance.
Digitate’s flagship product ignio™ is an end-to-end autonomous solution that uses advanced machine learning and AI capabilities to bring contextual intelligence to IT operations. ignio™ enables enterprises with a one-of-a-kind closed-loop solution that combines context, insights and intelligent automation to autonomously predict, prevent and prescribe for issues. Digitate is helping Fortune 500 companies harness the power of AI and automation as they scale to meet the demands of their own customers and ease the ever-increasing workload on IT teams.
"Our growth over the past few years speaks to the strength of our solutions in supporting our customers' goals for digital transformation success,” said Akhilesh Tripathi, CEO of Digitate. “Digitate is committed to providing customers an AI-driven, closed-loop platform that further improves productivity, business continuity, and customer experience. Our recognition as a market leader by several prominent analyst and industry reports is a validation of our investments and the adoption of our solutions across some of the world’s leading enterprises”
Digitate’s success is highlighted by several notable achievements and recognition in 2021, including:
- Named a leader in the Omdia “AIOps Universe – Selecting an AIOps Solution 2021 - 2022” Report – Due in part to its strong automation capabilities and management control, Digitate was recognized for its commitment to creating value for business functions through automation and comprehensive AIOps capabilities. Digitate was the leader in the overall customer experience with a recommendation score of 96%. To support Digitate’s all-rounder status, it scored 95% for solution breadth.
- Recognized on the Constellation Research ShortList™ for Using Artificial Intelligence in IT Operations (AIOps) Q3 2021 – Constellation’s list evaluated over 40 most prominent AIOps solutions based on client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research. Digitate was selected based on its noise reduction and enterprise capabilities, among other criteria.
- Recognized as a technology leader in Quadrant Knowledge Solution’s SPARKS Matrix for Artificial Intelligence for IT Operations (AIOps) Platform 2021 Report –The report pointed out some of the key differentiators that include Digitate’s over 10 000 out-of-the-box automation capabilities and unique, closed-loop system ensuring better ROI and lower time to value.
- Highlighted in the IDC Worldwide IT Operations Analytics Software Market Shares Report – Digitate was the second fastest-growing IT Operations Analytics software company for 2020, with a revenue growth rate of 43.5%. (August 2021, IDC #US48125121)
- Highlighted in the IDC Worldwide Workload Management Software Market Shares Report – Digitate was the fastest growing WLM software company for 2020 with a revenue growth rate of 75.6 %. (July 2021, IDC #US48063321)
About Digitate
Digitate is a leading software provider bringing agility, assurance, and resiliency to IT and business operations. Digitate’s flagship product ignio™ is an award-winning AIOps software that reimagines enterprise IT and business landscape with its unique and innovative closed-loop approach by combining context, insights and intelligent automation to autonomously resolve and prevent issues. Our customers span across industry verticals and include large, global enterprises that are leaders and innovators in their respective industries. Digitate is headquartered in Santa Clara, California, USA and Pune, India. To stay up to date on ignio™ news and to learn more how our clients across the globe have benefited from our innovative solutions: Visit us at www.digitate.com , and follow Digitate on Twitter and LinkedIn .
Learn more about our AIOps solution here: http://www.youtube.com/watch?v=xy3FGkbZNDM
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005225/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom